STOCK TITAN

Schrodinger Stock Price, News & Analysis

SDGR NASDAQ

Company Description

Company Overview

Schrodinger, Inc. stands as a unique enterprise where advanced molecular simulation technology meets impactful enterprise software solutions. The company is deeply rooted in transforming drug discovery and materials science research through innovative software and strategic research collaborations. Its dual operating segments—Software and Drug Discovery—serve a broad spectrum of customers in pharmaceuticals, biotechnology, and materials science industries, enhancing research precision and accelerating development timelines.

Core Business Areas

The company is organized into two fundamental segments:

  • Software Segment: This unit is dedicated to providing state-of-the-art molecular simulation software that aids scientists in optimizing research processes. By leveraging its predictive capabilities through advanced computational models, Schrodinger helps customers reduce research costs and streamline drug discovery pipelines.
  • Drug Discovery Segment: Focused on generating revenue from a diverse portfolio of preclinical and clinical programs, this segment operates through internally managed initiatives as well as strategic collaborations. It harnesses scientific insights and milestone-based research funding to push forward breakthroughs in therapeutic development and materials advancements.

Market Significance

Schrodinger’s innovative approach is built on the foundation of scientific research excellence and advanced technological application. The integration of cutting-edge molecular simulations within its software solutions offers a competitive advantage to researchers, supporting faster and more accurate decision-making processes. In an industry driven by complex R&D challenges, the company’s unique dual model positions it as an instrumental contributor to the progression of life sciences and materials research.

Scientific Impact and Expertise

Underpinning its commercial success is a robust commitment to science. Schrodinger’s significant investments in basic research have resulted in numerous scientific breakthroughs, which are frequently validated through peer-reviewed publications. This dedication to foundational research and evidence-based innovation not only reinforces the company's market credibility but also provides a roadmap for future scientific endeavors in drug discovery and beyond.

Collaborations and Strategic Partnerships

Collaboration stands at the heart of Schrodinger’s operational ethos. The company has established deep, long-term partnerships across various industries, including pharmaceuticals, biotechnology, chemicals, and electronics. By collaborating with key industry players and even contributing to ventures like biotechnology startups, Schrodinger extends its innovative reach and fosters a dynamic exchange of scientific expertise.

Competitive Landscape

In a competitive market characterized by rapid advancements in computational chemistry and software-driven research, Schrodinger differentiates itself through its integrated business model. By combining software-driven research tools with active participation in drug discovery programs, the company offers a comprehensive approach that addresses both immediate research needs and the broader, long-term challenges of drug development. Its focus on quality, scientific rigor, and technological innovation ensures that its solutions remain indispensable in an increasingly complex market environment.

Overall, Schrodinger, Inc. epitomizes a blend of scientific excellence and technological expertise that drives innovation across critical sectors. Its contributions to advanced molecular simulations, combined with a clear value proposition in transforming drug discovery and materials science research, make it a pivotal player in the evolution of modern research and development.

Stock Performance

$—
0.00%
0.00
Last updated:
-45.09 %
Performance 1 year
$1.9B
Market Cap
73.0M
Shares outstanding

SEC Filings

No SEC filings available for Schrodinger.

Financial Highlights

$207,539,000
Revenue (TTM)
-$187,123,000
Net Income (TTM)
-$2.57
Diluted EPS (TTM)
-$157,368,000
Operating Cash Flow
-90.16%
Net Profit Margin
-100.85%
Oper. Profit Margin

Frequently Asked Questions

What is the current stock price of Schrodinger (SDGR)?

The current stock price of Schrodinger (SDGR) is $26.45 as of April 25, 2025.

What is the market cap of Schrodinger (SDGR)?

The market cap of Schrodinger (SDGR) is approximately 1.9B.

What is the revenue (TTM) of Schrodinger (SDGR) stock?

The trailing twelve months (TTM) revenue of Schrodinger (SDGR) is $207,539,000.

What is the net income of Schrodinger (SDGR)?

The trailing twelve months (TTM) net income of Schrodinger (SDGR) is -$187,123,000.

What is the earnings per share (EPS) of Schrodinger (SDGR)?

The diluted earnings per share (EPS) of Schrodinger (SDGR) is -$2.57 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Schrodinger (SDGR)?

The operating cash flow of Schrodinger (SDGR) is -$157,368,000.

What is the profit margin of Schrodinger (SDGR)?

The net profit margin of Schrodinger (SDGR) is -90.16%.

What is the operating margin of Schrodinger (SDGR)?

The operating profit margin of Schrodinger (SDGR) is -100.85%.

What is the gross margin of Schrodinger (SDGR)?

The gross profit margin of Schrodinger (SDGR) is 63.64%.

What is the current ratio of Schrodinger (SDGR)?

The current ratio of Schrodinger (SDGR) is 3.31, indicating the company's ability to pay short-term obligations.

What is the gross profit of Schrodinger (SDGR)?

The gross profit of Schrodinger (SDGR) is $132,083,000 on a trailing twelve months (TTM) basis.

What is the operating income of Schrodinger (SDGR)?

The operating income of Schrodinger (SDGR) is -$209,296,000.

What is Schrodinger, Inc.'s core business model?

Schrodinger, Inc. operates through two primary segments: a Software segment that provides advanced molecular simulation tools, and a Drug Discovery segment that leverages strategic research collaborations. These activities support innovation in pharmaceutical and material science research.

How does Schrodinger generate revenue?

The company generates revenue from the sales of its enterprise software solutions and from research funding along with milestone payments through collaborations in drug discovery. This dual approach reflects its integrated business model.

Which industries benefit from Schrodinger's solutions?

Schrodinger serves a variety of industries including pharmaceuticals, biotechnology, and materials science. Its molecular simulation software is pivotal in accelerating research in life sciences and support fields such as chemical and electronics research.

What distinguishes Schrodinger's simulation software?

Its software is recognized for its advanced computational capabilities that deliver predictive insights to facilitate faster and more precise research. The technology not only supports cost reduction but also fosters breakthrough discoveries in drug development.

What role do collaborations play in Schrodinger's business?

Collaborations are central to Schrodinger’s approach; the company engages with leading pharmaceutical and biotechnology firms to drive innovative drug discovery programs. These partnerships enhance the application and trust in its software solutions.

How is scientific expertise reflected in the company's operations?

Schrodinger has consistently invested in basic research, resulting in a strong portfolio of peer-reviewed scientific publications. This rigorous approach underpins the credibility of its simulation software and the reliability of its research collaborations.

How does Schrodinger compare to competitors in its field?

By integrating advanced molecular simulations with active drug discovery programs, Schrodinger offers a more holistic solution compared to companies that focus solely on software or research alone. Its combination of technological innovation and scientific validation sets it apart in a competitive market.